Markers of inflammation and oxidative stress studied in adjuvant-induced arthritis in the rat on systemic and local level affected by pinosylvin and methotrexate and their combination

Autoimmunity

Volumn 48, Issue 1, 2015, Pages 46-56

  Bauerova, Katarina ^a   Acquaviva, Alessandra ^b   Ponist, Silvester ^a   Gardi, Concetta ^b   Vecchio, Daniela ^b   Drafi, Frantisek ^a   Arezzini, Beatrice ^b   Bezakova, Lydia ^c   Kuncirova, Viera ^a   Mihalova, Danica ^a   Nosal, Radomir ^a  

^a INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

^b UNIVERSITY OF SIENA   (Italy)

^c Department of Pharmaceutical Analysis and Nuclear Pharmacy   (Slovakia)

Author keywords

Antioxidants; Autoimmunity; Combination therapy; Extra articular manifestation; Rheumatoid arthritis

Indexed keywords

BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOPROSTANE DERIVATIVE; LIPOXYGENASE; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; PINOSYLVIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CCL2 PROTEIN, RAT; CHEMOKINE CCL2; F2-ISOPROSTANES; GAMMA-GLUTAMYLTRANSFERASE; HEME OXYGENASE-1; NF-KAPPA B; STILBENES; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; INFLAMMATION; MALE; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; ANIMALS; ARTHRITIS, EXPERIMENTAL; BLOOD; DRUG EFFECTS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HINDLIMB; LIVER; LUNG; METABOLISM; PATHOLOGY; RATS; RATS, INBRED LEW; SPLEEN;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHEMOKINE CCL2; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; F2-ISOPROSTANES; GAMMA-GLUTAMYLTRANSFERASE; HEME OXYGENASE-1; HINDLIMB; INFLAMMATION; LIPOXYGENASE; LIVER; LUNG; MALE; METHOTREXATE; NF-KAPPA B; OXIDATIVE STRESS; RATS; RATS, INBRED LEW; SPLEEN; STILBENES; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 84919798083     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2014.939268     Document Type: Article

References (63)

1. Karmakar, S., J. Kay, and E. M. Gravallese. (2010). Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. Rheum. Dis. Clin. North. Am. 36: 385-404.
2. Bauerova, K., E. Paulovicova, D. Mihalova, et al. (2009). Study of new ways of supplementary and combinatory therapy of rheumatoid arthritis with immunomodulators. Glucomannan and Imunoglukan® in adjuvant arthritis. Toxicol. Ind. Health. 25: 329-335.
3. Firestein, G. S. (2003). Evolving concepts of rheumatoid arthritis. Nature. 423: 356-361.
4. Cascao, R., H. S. Rosario, M. M. Souto-Carneiro, and J. E. Fonseca. (2010). Neutrophils in rheumatoid arthritis: more than simple final effectors. Autoimmun. Rev. 9: 531-535.
5. Drabikova, K., T. Perecko, R. Nosal, et al. (2009). Glucomannan reduces neutrophil free radical production in vitro and in rats with adjuvant arthritis. Pharmacol. Res. 59: 399-403.
6. Ponist, S., D. Mihalova, V. Jancinova, et al. (2010). Reduction of oxidative stress in adjuvant arthritis. Comparison of efficacy of two pyridoindoles: stobadine dipalmitate and SMe1.2HCl. Acta Biochim. Pol. 57: 223-228.
7. Lipsky, P. E., and A. F. Kavanaugh. (2001). Rheumatoid arthritis. In Clinical Imunology, 2nd ed. R. R. Rich, ed. Mosby, London, p. 61.
8. McLean-Tooke, A., C. Aldridge, S. Waugh, et al. (2009). Methotrexate, rheumatoid arthritis and infection risk: what is the evidence? Rheumatology (Oxford). 48: 867-871.
9. Weinblatt, M. E. (2003). Rheumatoid arthritis in (2003): where are we now with treatment? Ann. Rheum. Dis. 62: 94-96.
10. Bauerova, K., E. Paulovicova, D. Mihalova, et al. (2010). Combined methotrexate and coenzyme Q10 therapy in adjuvant-induced arthritis evaluated using parameters of inflammation and oxidative stress. Acta Biochim. Pol. 57: 347-354.
11. Bauerova, K., S. Ponist, D. Mihalova, et al. (2011). Utilization of adjuvant arthritis model for evaluation of new approaches in rheumatoid arthritis therapy focused on regulation of immune processes and oxidative stress. Interdiscip. Toxicol. 4: 33-39.
12. Smolen, J. S., D. Aletaha, J. W. Bijlsma, et al. (2010). Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 69: 631-637.
13. Pigott, E., J. B. Duhadaway, A. J. Muller, et al. (2014). 1-Methyl-tryptophan synergizes with methotrexate to alleviate arthritis in a mouse model of arthritis. Autoimmunity. [Epub ahead of print]. Posted online on May 6, (2014). doi:10.3109/08916934.(2014).914507.
14. Park, E. J., H. J. Park, H. J. Chung, et al. (2012). Antimetastatic activity of pinosylvin, a natural stilbenoid, is associated with the suppression of matrix metalloproteinases. J. Nutr. Biochem. 23: 946-952.
15. Park, E. J., H. J. Chung, H. J. Park, et al. (2013). Suppression of Src/ERK and GSK-3/b-catenin signaling by pinosylvin inhibits the growth of human colorectal cancer cells. Food Chem. Toxicol. 55: 424-433.
16. Jancinova, V., R. Nosal, A. Lojek, et al. (2010). Formation of reactive oxygen and nitrogen species in the presence of pinosylvin-an analogue of resveratrol. Neuro. Endocrinol. Lett. 31: 79-83.
17. Macickova, T., K. Drabikova, R. Nosal, et al. (2010). In vivo effect of pinosylvin and pterostilbene in the animal model of adjuvant arthritis. Neuro. Endocrinol. Lett. 31: 91-95.
18. Jancinova, V., T. Perecko, R. Nosal, et al. (2012). The natural stilbenoid pinosylvin and activated neutrophils: effects on oxidative burst, protein kinase C, apoptosis and efficiency in adjuvant arthritis. Acta Pharmacol. Sin. 33: 1285-1292.
19. Brown, R. K., and F. J. Kelly. (1996). Peroxides and other products. In Free Radicals, A Practical Approach. N. A. Punchard and F. J. Kelly, eds. Oxford University Press, Oxford. p. 119-131.
20. Ondrejickova, O., A. Ziegelhoeffer, I. Gabauer, et al. (1993). Evaluation of ischemia-reperfusion injury by malondialdehyde, glutathione and gamma-glutamyl transpeptidase: lack of specific local effects in diverse parts of the dog heart following acute coronary occlusion. Cardioscience. 4: 225-230.
21. Kemal, C., P. Louis-Flamberg, R. Krupinski-Olsen, and A. L. Shorter. (1987). Reductive inactivation of soybean lipoxygenase 1 by catechols: a possible mechanism for regulation of lipoxygenase activity. Biochemistry. 26: 7064-7072.
22. Bauerova, K., S. Ponist, V. Kuncirova, et al. (2011). Chondroitin sulfate effect on induced arthritis in rats. Osteoarthritis Cartilage. 19: 1373-1379.
23. Connolly, K. M., V. J. Stecher, E. Danis, et al. (1988). Alteration of interleukin-1 production and the acute phase response following medication of adjuvant arthritic rats with cyclosporin-A or metho-trexate. Int. J. Immunopharmacol. 10: 717-728.
24. Feketeova, L., P. Jancova, P. Moravcova, et al. (2012). Effect of methotrexate on inflammatory cells redistribution in experimental adjuvant arthritis. Rheumatol. Int. 32: 3517-3523.
25. Rovensky, J., K. Svik, E. Rovenska, et al. (2008). Effects of purified micronized flavonoid fraction (Detralex) on prophylactic treatment of adjuvant arthritis with methotrexate in rats. Isr. Med. Assoc. J. 10: 377-380.
26. Jurcovicova, J., K. Svik, S. Scsukova, et al. (2009). Methotrexate treatment ameliorated testicular suppression and anorexia related leptin reduction in rats with adjuvant arthritis. Rheumatol. Int. 29: 1187-1191.
27. Kunsch, C., J. A. Sikorski, and C. L. Sundell. (2005). Oxidative stress and the use of antioxidants for the treatment of rheumatoid arthritis. Curr. Med. Chem.-Immun., Endoc. Metab. Agents. 5: 249-258.
28. Bauerova, K., J. Kucharska, D. Mihalova, et al. (2005). Effect of coenzyme Q(10) supplementation in the rat model of adjuvant arthritis. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech. Repub. 149: 501-503.
29. Kogan, G., A. Stasko, K. Bauerova, et al. (2005). Antioxidant properties of yeast (1-3)-b-D-glucan studied by electron paramagnetic resonance spectroscopy and its activity in the adjuvant arthritis. Carbohydr. Polym. 61: 18-28.
30. Mihalova, D., S. Ponist, J. Kucharska, et al. (2007). Total antioxidant status-systemic marker of oxidative stress in adjuvant arthritis. Chemicke. Listy. 101: 225-226.
31. Bauerova, K., J. Valentova, S. Ponist, et al. (2005). Effect of copper complexes on the development of adjuvant arthritis: therapeutic and toxicological aspects. Biologia. 60: 65-68.
32. Bauerova, K., S. Ponist, J. Navarova, et al. (2008). Glucomannan in prevention of oxidative stress and inflammation occuring in adjuvant arthritis. Neuro. Endocrinol. Lett. 29: 691-696.
33. He, Y. H., J. Zhou, Y. S. Wang, et al. (2006). Antiinflammatory and anti-oxidative effects of cherries on Freund's adjuvant-induced arthritis in rats. Scand. J. Rheumatol. 35: 356-358.
34. Tastekin, N., N. Aydogdu, D. Dokmeci, et al. (2007). Protective effects of L-carnitine and alpha-lipoic acid in rats with adjuvant arthritis. Pharmacol. Res. 56: 303-310.
35. Comporti, M., C. Signorini, B. Arezzini, et al. (2008). F2-isoprostanes are not just markers of oxidative stress. Free Radic. Biol. Med. 44: 247-256.
36. Comporti, M., C. Signorini, B. Arezzini, et al. (2008). Isoprostanes and hepatic fibrosis. Mol. Aspects. Med. 29: 43-49.
37. Basu, S., M. Whiteman, D. L. Mattey, and B. Halliwell. (2001). Raised levels of F(2)-isoprostanes and prostaglandin F(2alpha) in different rheumatic diseases. Ann. Rheum. Dis. 60: 627-631.
38. Devasagayam, T. P. 1, K. K. Boloor, and T. Ramasarma. (2003). Methods for estimating lipid peroxidation: an analysis of merits and demerits. Indian J. Biochem. Biophys. 40: 300-308.
39. Bauerova, K., S. Ponist, O. Ondrejickova, et al. (2006). Association between tissue gamma-glutamyl-transferase and clinical markers of adjuvant arthritis in Lewis rats. Neuro. Endocrinol. Lett. 27: 172-175.
40. Ishizuka, Y., S. Moriwaki, M. Kawahara-Hanaoka, et al. (2007). Treatment with anti-gamma-glutamyl transpeptidase antibody attenuates osteolysis in collagen-induced arthritis mice. J. Bone Miner. Res. 22: 1933-1942.
41. Rambabu, K., A. A. Ansari, I. A. Shaafie, et al. (1990). Gamma-glutamyl transpeptidase in synovial fluid, serum, and urine of patients with rheumatoid arthritis. Biochem. Med. Metab. Biol. 43: 183-192.
42. Drafi, F., K. Bauerova, V. Kuncirova, et al. (2012). Pharmacological influence on processes of adjuvant arthritis: effect of the combination of an antioxidant active substance with methotrexate. Interdiscip. Toxicol. 5: 84-91.
43. Nguyen, T., P. Nioi, and C. B. Pickett. (2009). The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem. 284: 13291-13295.
44. Ryter, S. W., H. P. Kim, K. Nakahira, et al. (2007). Protective functions of heme oxygenase-1 and carbon monoxide in the respiratory system. Antioxid. Redox. Signal. 9: 2157-2173.
45. Liote, H. (2008). Pulmonary manifestation of rheumatoid arthritis. Rev. Mal. Respir. 25: 973-988.
46. Ridker, P. M. (2001). Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial. Eur. Heart J. 22: 2135-2137.
47. Rollins, B. J. (1996). Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol. Med. Today. 12: 198-204.
48. Nathan, C. (2003). Immunology: oxygen and the inflammatory cell. Nature. 422: 675-676.
49. Alghasham, A., Z., Rasheed. (2014). Therapeutic targets for rheumatoid arthritis: progress and promises. Autoimmunity. 47: 77-94.
50. Makarov, SS. (2001). NF-kB in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res. 3: 200-206.
51. van Loo, G., and R. Beyaert. (2011). Negative regulation of NF-kB and its involvement in rheumatoid arthritis. Arthritis Res. Ther. 13: 221.
52. Ren, Z., L. Wang, J. Cui, et al. (2013). Resveratrol inhibits NF-kB signaling through suppression of p65 and IkappaB kinase activities. Pharmazie. 68: 689-694.
53. Lei, M., J. G. Wang, D. M. Xiao, et al. (2012). Resveratrol inhibits interleukin 1b-mediated inducible nitric oxide synthase expression in articular chondrocytes by activating SIRT1 and thereby suppressing nuclear factor-kB activity. Eur. J. Pharmacol. 674: 73-79.
54. Prete, M., V. Racanelli, L. Digiglio, et al. (2011). Extra-articular manifestations of rheumatoid arthritis: an update. Autoimmun. Rev. 11: 123-131.
55. Renju, G. L., G. Muraleedhara Kurup, and C. H. Saritha Kumari. (2013). Anti-inflammatory activity of lycopene isolated from chlorella marina on type II collagen induced arthritis in Sprague Dawley rats. Immunopharmacol. Immunotoxicol. 35: 282-291.
56. Gay, R. E., M. Neidhart, F. Pataky, et al. (2001). Dual inhibition of 5-lipoxygenase and cyclooxygenases 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis. J. Rheumatol. 28: 2060-2065.
57. Kumar, K. S., V. Vijayan, S. Bhaskar, et al. (2012). Anti-inflammatory potential of an ethyl acetate fraction isolated from Justicia gendarussa roots through inhibition of iNOS and COX-2 expression via NF-kB pathway. Cell. Immunol. 272: 283-289.
58. Lee, J., E. Jung, J. Lim, et al. (2006). Involvement of nuclear factor-kappaB in the inhibition of pro-inflammatory mediators by pinosylvin. Planta. Med. 72: 801-806.
59. Roupe, K. A., C. M. Remsberg, J. A. Yanez, and N. M. Davies. (2006). Pharmacometrics of stilbenes: seguing towards the clinic. Curr. Clin. Pharmacol. 1: 81-101.
60. Adams, M., T. Pacher, H. Greger, and R. Bauer. (2005). Inhibition of leukotriene biosynthesis by stilbenoids from Stemona species. J. Nat. Prod. 68: 83-85.
61. Lewis, R. A., K. F. Austen, and R. J. Soberman. (1990). Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N. Engl. J. Med. 323: 645-655.
62. Frankel, D., K. Mehindate, and H. M. Schipper. (2000). Role of heme oxygenase-1 in the regulation of manganese superoxide dismutase gene expression in oxidatively-challenged astroglia. J. Cell. Physiol. 185: 80-86.
63. Zhang, J., and C. A. Piantadosi. (1992). Mitochondrial oxidative stress after carbon monoxide hypoxia in the rat brain. J. Clin. Invest. 90: 1193-1199.